2-(4-methyl-1-piperazinyl)aniline, also known as **N-(4-methylpiperazin-1-yl)benzenamine**, is an organic compound that has a significant role in research due to its potential as a building block for various pharmaceutical and material applications.
**Here's a breakdown of its importance:**
**1. Building Block for Pharmaceuticals:**
* **Antidepressant Activity:** This compound serves as a precursor for the synthesis of several antidepressants. Its structural similarity to known serotonin reuptake inhibitors (SSRIs) makes it a promising starting point for developing new antidepressant therapies.
* **Anticancer Activity:** Research suggests that derivatives of this compound may exhibit anticancer activity. This is due to their ability to interact with specific cellular targets involved in cancer cell growth and proliferation.
* **Other Therapeutic Applications:** 2-(4-methyl-1-piperazinyl)aniline can be used as a starting point for synthesizing compounds with diverse pharmacological activities, including antihistamines, anti-inflammatory agents, and antipsychotics.
**2. Materials Science:**
* **Organic Electronics:** This compound can be used as a building block for organic semiconductors, which are key components of organic light-emitting diodes (OLEDs), solar cells, and other organic electronic devices.
* **Polymer Synthesis:** Derivatives of 2-(4-methyl-1-piperazinyl)aniline can be incorporated into polymers to enhance their conductivity, optical properties, and mechanical strength. This opens up possibilities for developing new materials with specific functionalities.
**3. Research Tool:**
* **Chemical Synthesis:** It serves as a versatile reagent in organic synthesis, allowing for the creation of new molecules with diverse properties. Its reactivity and functional groups make it suitable for a wide range of reactions.
* **Biological Research:** 2-(4-methyl-1-piperazinyl)aniline can be used as a probe to study biological systems and processes. For instance, its derivatives can be labelled with radioactive isotopes or fluorescent tags to track their distribution and interaction with specific biological targets.
**Overall, 2-(4-methyl-1-piperazinyl)aniline is a versatile compound with vast potential in research. Its unique chemical structure and reactivity make it an invaluable tool for developing new pharmaceuticals, materials, and understanding biological processes.**
**It's important to note that the specific applications and research interests related to this compound can vary significantly.** If you're interested in learning more about its specific uses in a particular field, you should consult specialized scientific literature and databases.
ID Source | ID |
---|---|
PubMed CID | 286547 |
CHEMBL ID | 1879790 |
CHEBI ID | 113157 |
SCHEMBL ID | 1926749 |
Synonym |
---|
AC-3593 |
180605-36-1 |
smr000121448 |
MLS000528973 |
EN300-11843 |
BB 0245145 |
2-(4-methyl-1-piperazinyl)aniline |
nsc145003 |
nsc-145003 |
2-(4-methyl-piperazin-1-yl)-phenylamine |
STK141998 |
2-(4-methylpiperazin-1-yl)aniline |
CHEBI:113157 |
AKOS000103050 |
chembl1879790 , |
bdbm50097721 |
A835370 |
A4002 |
1-(2-aminophenyl)-4-methylpiperazine |
2-(4-methyl-1-piperazinyl)-benzenamine |
HMS2318E12 |
AM803393 |
FT-0643742 |
2-(4-methylpiperazino)aniline |
CL1602 |
mfcd04035359 |
SY007572 |
SCHEMBL1926749 |
PS-5147 |
2-(4-methylpiperazin-1-yl)-aniline |
INWHDRNGZMHXEZ-UHFFFAOYSA-N |
W-206285 |
M2592 |
Q27193623 |
2-(4-methylpiperazin-1-yl)aniline, aldrichcpr |
benzenamine, 2-(4-methyl-1-piperazinyl)- |
DTXSID60301626 |
Z57625083 |
CS-W003132 |
F1911-3703 |
QSS , |
2-(4-methylpiperazine)aniline |
6-amino-3,4-dihydro-2h-pyrido[2,3-e][1,2,4]thiadiazine-7-sulfonamide 1,1-dioxide |
Class | Description |
---|---|
piperazines | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
GLS protein | Homo sapiens (human) | Potency | 31.6228 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
geminin | Homo sapiens (human) | Potency | 25.9290 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.2399 | 0.0003 | 0.4834 | 10.0000 | AID1232265 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
alpha2-adrenergic receptor activity | Alpha-2C adrenergic receptor | Homo sapiens (human) |
protein binding | Alpha-2C adrenergic receptor | Homo sapiens (human) |
alpha-2A adrenergic receptor binding | Alpha-2C adrenergic receptor | Homo sapiens (human) |
protein homodimerization activity | Alpha-2C adrenergic receptor | Homo sapiens (human) |
protein heterodimerization activity | Alpha-2C adrenergic receptor | Homo sapiens (human) |
epinephrine binding | Alpha-2C adrenergic receptor | Homo sapiens (human) |
guanyl-nucleotide exchange factor activity | Alpha-2C adrenergic receptor | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
cytoplasm | Alpha-2C adrenergic receptor | Homo sapiens (human) |
endosome | Alpha-2C adrenergic receptor | Homo sapiens (human) |
plasma membrane | Alpha-2C adrenergic receptor | Homo sapiens (human) |
plasma membrane | Alpha-2C adrenergic receptor | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1232269 | Antagonist activity at recombinant human alpha2c adrenergic receptor expressed in CHOK1 cells co-expressing Gqi5 assessed as inhibition of UK14304-induced cytoplasmic calcium mobilization at 20 uM preincubated for 15 mins by fluorometric analysis relative | 2015 | Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14 | Cell-based and virtual fragment screening for adrenergic α2C receptor agonists. |
AID1232265 | Displacement of [3H]-UK14304 from recombinant human alpha2c adrenergic receptor expressed in CHOK1 cell membranes after 30 mins by scintillation counting analysis | 2015 | Bioorganic & medicinal chemistry, Jul-15, Volume: 23, Issue:14 | Cell-based and virtual fragment screening for adrenergic α2C receptor agonists. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |